β³ Fetching live dividend data...
Home βΊ Calculator βΊ PTCT Dividend Calculator 2026
PTC Therapeutics, Inc. Β· NASDAQ
Price: $61.07 Β· Annual div: None Β· Frequency: β Β· Payout ratio: N/A Β· Ex-div: β
PTCT is not a dividend-focused stock
PTCT pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
PTC Therapeutics, Inc. (PTCT) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of developmentβfrom early research and preclinical studies to clinical trialsβwith a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
No. PTC Therapeutics, Inc. (PTCT) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
A DRIP reinvests dividends into new shares. PTCT has no regular dividend in our data, so there is nothing to reinvest.
Forward dividend yield from the latest data Β· open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. Β· Privacy Policy
Ready to invest? Open PTCT position with:
Real after-tax yield depends on where you live and how you hold PTCT.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| πΊπΈ Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| πΊπΈ US Taxable (15%) β | 15% | 0.00% | -2.80% | $0 / yr |
| πΊπΈ US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| π¬π§ UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| π¬π§ UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| π¨π¦ TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| π¨π¦ CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| π¦πΊ Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| π¦πΊ AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| π©πͺ DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| π«π· FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
PTCT pays quarterly β 4 times per year. Ex-div: β.
How PTCT compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for PTCT sourced from FMP /financial-growth endpoint β real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Sale | 2026-10-14 | 2,118 | $59.52 | $126.1K | ||
| Sale | 2026-10-14 | 382 | $60.14 | $23.0K | ||
| M-Exempt | 2026-10-09 | 192 | $39.42 | $7.6K | ||
| Sale | 2026-10-09 | 192 | $64.26 | $12.3K | ||
| M-Exempt | 2026-10-09 | 192 | $39.42 | $7.6K | ||
| Sale | 2026-10-07 | 2,447 | $63.38 | $155.1K | ||
| Sale | 2026-10-07 | 53 | $63.95 | $3.4K | ||
| M-Exempt | 2026-10-05 | 1,638 | $39.42 | $64.6K | ||
| M-Exempt | 2026-10-06 | 435 | $39.42 | $17.1K | ||
| Sale | 2026-10-05 | 1,638 | $64.03 | $104.9K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Compare PTCT with peers: PTCT vs ACLX Β· PTCT vs ALKS Β· PTCT vs ARWR
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores β lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the PTCT dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β
PTC Therapeutics, Inc. (PTCT) is currently trading at $61.07, trading near its 52-week low. It does not currently pay a regular dividend.
PTC Therapeutics, Inc. (PTCT) is a healthcare stock trading at $61.07. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
Auto-generated from live market data. For educational purposes only β not financial advice.
News aggregated from public sources via Finnhub & RSS. For informational purposes only.
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
β±οΈ Takes 30 seconds Β· No signup Β· Free forever